Whitelab Genomics
WhiteLab Genomics provides an AI-driven platform that speeds discovery and design of genomic therapies, reducing time and experimental workload. It combines graph knowledge technology, machine learning, and advanced computational biology to perform in-silico design and optimization of vectors, payloads, genotoxicity assessment, and experimental protocols. The platform supports modalities including AAV, lentiviral, and nanoparticle delivery and is used by biopharmaceutical companies and research institutions. WhiteLab's tools integrate into genomic R&D workflows to de-risk early development and accelerate candidate selection for downstream preclinical testing.
Whitelab Genomics
WhiteLab Genomics provides an AI-driven platform that speeds discovery and design of genomic therapies, reducing time and experimental workload. It combines graph knowledge technology, machine learning, and advanced computational biology to perform in-silico design and optimization of vectors, payloads, genotoxicity assessment, and experimental protocols. The platform supports modalities including AAV, lentiviral, and nanoparticle delivery and is used by biopharmaceutical companies and research institutions. WhiteLab's tools integrate into genomic R&D workflows to de-risk early development and accelerate candidate selection for downstream preclinical testing.
TL;DR
What they do: AI-driven platform (ALFRED AI) for design and optimization of genomic medicines (AAV, lentiviral, non-viral vectors, payloads, bioproduction)
Founded: 2019
Headquarters / presence: Paris, Boston, Montréal
Funding: $10M seed (Sep 12, 2022); pre-seed tied to Y Combinator (Mar 2022)
Investors / partners: Debiopharm Group, Omnes Capital, Y Combinator
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Accelerating and de-risking genomic medicine R&D (gene and cell therapy development).
Founded
2019
Industry
Biotechnology
Tech Stack
Funding Track Record
Pre-seed round associated with Y Combinator
10000000
Seed round announced Sep 12, 2022
Investor Signal
“Debiopharm Group and Omnes Capital are lead investors; Y Combinator participated in earlier round”